Abstract
The innate immune system accounts for the fastest defense response to microbial invasion although, conversely, several pathogens can modulate the host response resulting in a modulation of their survival and propagation. In this regard, some bacterial toxins possess immuno-stimulating properties that have been exploited in terms of vaccine adjuvanticity and induction of specific cytotoxic T lymphocytes. Among these, Bordetella pertussis toxin (PTX) possesses the ability of modulating the immune responses in multiple ways, as demonstrated in vivo as well as in ex-vivo and in vitro experimental systems. In addition, PTX, as well its nontoxic B-oligomer PTX-B and the genetically inactivated PT-9K/129G molecule, have been recently shown to inhibit infection of primary cells, lymphoid organs and cervical tissue by the human immunodeficiency virus type 1 (HIV-1), the etiological agent of the acquired immunodeficiency syndrome. This article focuses on the regulation of the immune response and on the anti-viral properties of PTX and of its nontoxic related molecules as an example of exploitation of a natural bacterial product to combat viral infections.
Keywords: Pertussis toxin, HIV, tat, intracellular signaling, protein kinase C, adjuvant, microbicide.
Anti-Inflammatory & Anti-Allergy Agents in Medicinal Chemistry
Title:Pertussis Toxin (PTX) and its Non-Toxic Derivatives as Vaccine Adjuvant and Microbicide
Volume: 10 Issue: 5
Author(s): Massimo Alfano and Guido Poli
Affiliation:
Keywords: Pertussis toxin, HIV, tat, intracellular signaling, protein kinase C, adjuvant, microbicide.
Abstract: The innate immune system accounts for the fastest defense response to microbial invasion although, conversely, several pathogens can modulate the host response resulting in a modulation of their survival and propagation. In this regard, some bacterial toxins possess immuno-stimulating properties that have been exploited in terms of vaccine adjuvanticity and induction of specific cytotoxic T lymphocytes. Among these, Bordetella pertussis toxin (PTX) possesses the ability of modulating the immune responses in multiple ways, as demonstrated in vivo as well as in ex-vivo and in vitro experimental systems. In addition, PTX, as well its nontoxic B-oligomer PTX-B and the genetically inactivated PT-9K/129G molecule, have been recently shown to inhibit infection of primary cells, lymphoid organs and cervical tissue by the human immunodeficiency virus type 1 (HIV-1), the etiological agent of the acquired immunodeficiency syndrome. This article focuses on the regulation of the immune response and on the anti-viral properties of PTX and of its nontoxic related molecules as an example of exploitation of a natural bacterial product to combat viral infections.
Export Options
About this article
Cite this article as:
Alfano Massimo and Poli Guido, Pertussis Toxin (PTX) and its Non-Toxic Derivatives as Vaccine Adjuvant and Microbicide, Anti-Inflammatory & Anti-Allergy Agents in Medicinal Chemistry 2011; 10 (5) . https://dx.doi.org/10.2174/1871523011109050358
DOI https://dx.doi.org/10.2174/1871523011109050358 |
Print ISSN 1871-5230 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-614X |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Fumaric Acid and its Esters: An Emerging Treatment for Multiple Sclerosis
Current Neuropharmacology Mechanism by which Regulatory Rheumatoid Factor Prevents Experimental Autoimmune Encephalomyelitis
Endocrine, Metabolic & Immune Disorders - Drug Targets Brain Innate Immunity in the Regulation of Neuroinflammation: Therapeutic Strategies by Modulating CD200-CD200R Interaction Involve the Cannabinoid System
Current Pharmaceutical Design Therapeutic Approach to Multiple Sclerosis by Novel Oral Drugs
Recent Patents on Inflammation & Allergy Drug Discovery MIP-1α and MCP-1 Induce Migration of Human Umbilical Cord Blood Cells in Models of Stroke
Current Neurovascular Research Herbal Phytochemicals as Immunomodulators
Current Immunology Reviews (Discontinued) Are B Cells a Potential Target for Therapeutic Intervention in the Classical T Cell-Mediated Autoimmune Disease Type 1 Diabetes?
Inflammation & Allergy - Drug Targets (Discontinued) “Self-Nonself” Peptides in the Design of Vaccines
Current Pharmaceutical Design Clinical Significance of Cytokines and Chemokines in Neuropsychiatric Systemic Lupus Erythematosus
Current Rheumatology Reviews Clinical and Pharmacological Aspects of Inflammatory Demyelinating Diseases in Childhood: An Update
Current Neuropharmacology The Extra-Hematopoietic Role of Erythropoietin in Diabetes Mellitus
Current Diabetes Reviews Apoptotic Cell Clearance and Autoimmune Disorder
Current Medicinal Chemistry Cross-Talk Between NO Synthase Isoforms in Neuro-Inflammation: Possible Implications in HIV-Associated Neurocognitive Disorders
Current Medicinal Chemistry Fibrinogen Signal Transduction as a Mediator and Therapeutic Target in Inflammation:Lessons from Multiple Sclerosis
Current Medicinal Chemistry The Role of Anaphylatoxins C3a and C5a in Regulating Innate and Adaptive Immune Responses
Inflammation & Allergy - Drug Targets (Discontinued) Fibroblast Growth Factors, Fibroblast Growth Factor Receptors, Diseases, and Drugs
Recent Patents on Cardiovascular Drug Discovery Emerging Role of Regulatory T Cells in Gene Transfer
Current Gene Therapy Metabotropic Glutamate Receptors and Interacting Proteins: Evolving Drug Targets
Current Drug Targets Drugs Targeting the Canonical NF-κB Pathway to Treat Viral and Autoimmune Myocarditis
Current Pharmaceutical Design Autoimmune Diseases and Atherosclerosis: The Inflammatory Connection
Current Immunology Reviews (Discontinued)